Homodimeric Fragment Crystallizable Fusion Protein Comprised Of The Extracellular Domain Of The Human Transforming Growth Factor Beta Receptor Type Ii Linked To A Human Igg1 Fc Domain
Systemic Sclerosis
Explore 25 assets in Systemic Sclerosis →Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
Merck Sharp & Dohme LLC
Modality
protein_peptide
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06643390CT.gov A Study of MK-2225 in Healthy Participants (MK-2225-003) | — | Completed | — | — | — |
NCT04948554CT.gov A Study of MK-2225 / ACE-1334 in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease (MK-2225-002) | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Systemic Sclerosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Homodimeric Fragment Crystallizable Fusion Protein Comprised Of The Extracellular Domain Of The Human Transforming Growth Factor Beta Receptor Type Ii Linked To A Human Igg1 Fc Domain (this asset) | Merck Sharp & Dohme LLC | P1 | CC · 47 |
| Cyclophosphamide | Royal Brompton & Harefield NHS Foundation Trust | P2/3 | BB |
| Iloprost | National Center for Research Resources (NCRR) | P3 | BB |
| Bosentan | Actelion | P3 | B |
| Rituximab | Royal Brompton & Harefield NHS Foundation Trust | P2/3 | B |
| Anti-Human T-Lymphocyte Immunoglobulin, Rabbit | Fred Hutchinson Cancer Center | P2 | B |
| Recombinant Humanised Igg1 Kappa Anti-Oncostatin M Monoclonal Antibody Gsk2330811 | GlaxoSmithKline | P2 | B |
| Human Relaxin 1 | National Center for Research Resources (NCRR) | P2 | B |
| Nivestim | Fred Hutchinson Cancer Center | P2 | B |
+33 more in the Systemic Sclerosis cohort
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Homodimeric Fragment Crystallizable Fusion Protein Comprised Of The Extracellular Domain Of The Human Transforming Growth Factor Beta Receptor Type Ii Linked To A Human Igg1 Fc Domain in Systemic Sclerosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/homodimeric-fragment-crystallizable-fusion-protein-comprised-of-the-extracellular-domain-of-the-human-transforming-growth-factor-beta-receptor-type-ii-linked-to-a-human-igg1-fc-domain-systemic-sclerosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →